Hyderabad: Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, has announced the inauguration of its new Biopharma Experience Center in Hyderabad, Telangana. This state-of-the-art facility represents a major investment in India’s rapidly expanding life sciences ecosystem and underscores Agilent’s long-term commitment to driving biopharmaceutical innovation locally and globally. The center was inaugurated by Duddila Sridhar Babu, Minister for Information Technology, Electronics, Communications, and Industries, Government of Telangana, in the presence of Agilent President and CEO Padraig McDonnell, along with senior leaders from India’s pharmaceutical and biopharma sectors.
The newly launched Agilent Biopharma Experience Center in Hyderabad is set to accelerate the city’s position as a hub for life sciences and healthcare innovation. Purpose-built to support the entire drug development journey, the center integrates cutting-edge laboratory technologies, specialized training, and regulatory-ready workflows, enabling researchers, scientists, and companies to develop high-quality, life-saving medicines more efficiently. It provides comprehensive solutions across key modalities such as chromatography, mass spectrometry, cell analysis, and lab informatics, offering the ability to simulate real lab environments, ensure quality and compliance, and co-create market-ready solutions for both Indian and global markets.
For Hyderabad’s thriving ecosystem of startups, academic institutions, and skilled professionals, the new center offers direct access to global expertise, state-of-the-art instrumentation, and real-world application environments. It enables faster R&D, hands-on training aligned with international regulatory standards, and deeper collaboration between industry and academia. By tackling critical challenges in biosimilars, biologics, and precision medicine, the facility reinforces Hyderabad’s reputation as a trusted global hub for next-generation drug development and a pivotal driver of India’s biopharma growth story.
India is a strategic growth market for Agilent, and Hyderabad stands at the forefront of biopharma innovation,” said Padraig McDonnell, CEO of Agilent Technologies. “Our future will be shaped by continuous innovation and an unwavering focus on our customers. This new center demonstrates our commitment to delivering integrated solutions that accelerate the development of life-changing therapies. It also underscores our support for the ‘Make-in-India’ initiative by fostering local innovation, nurturing talent, and enabling scalable, affordable, and sustainable solutions.
Located in the heart of India’s life sciences capital, the new Agilent Biopharma Experience Center is designed to close critical gaps in analytical capabilities and regulatory readiness for biopharma companies. The center will serve as a hub for innovation and collaboration, supporting the development of biologics, biosimilars, and precision medicine.
Sridhar Babu, Hon’ble Minister for Information Technology, Electronics, Communications, and Industries, Government of Telangana, said, “Hyderabad has evolved into a comprehensive healthcare and life sciences ecosystem—from drug discovery and clinical trials to world-class hospitals and affordable, high-quality patient care. We are proud to host eight of the top ten global pharma companies, five of India’s leading healthcare chains, and over 230 USFDA-approved manufacturing facilities. Contributing nearly one-third of India’s pharmaceutical production and 40% of bulk drug exports, Telangana is making a strong impact both nationally and globally. With a strong talent base and a clear focus on innovation, we are building a future-ready healthcare system. The launch of the Agilent Biopharma Experience Center is a significant milestone in strengthening Telangana’s position as a global leader in life sciences and a valuable addition to our expanding innovation-driven ecosystem.”
Hyderabad offers one of the most advanced and future-focused life sciences ecosystems in India, blending deep industry expertise, robust R&D capabilities, and a progressive policy environment. With its strong legacy in generics and a growing focus on advanced therapies, the city is well-positioned for the next phase of healthcare innovation.
The launch of the Agilent Biopharma Experience Center builds on this foundation by introducing advanced analytical and regulatory capabilities that support both local innovation and global delivery. This investment is a key part of Agilent’s three-to-five-year India growth strategy, which includes expanding its footprint, strengthening customer partnerships, and positioning India as a strategic hub in Agilent’s global innovation and profitability roadmap.
The India Solution Center in Manesar, launched earlier this year, further demonstrates this commitment—helping Agilent enhance its presence and capabilities in one of its fastest-growing, high-priority markets globally.
“Agilent is already working closely with many of India’s leading biopharma companies,” added McDonnell. “With this center, we aim to deepen those relationships and co-create solutions that address the evolving needs of both Indian and global markets.”
This milestone marks a new chapter in Agilent’s journey with India—fostering collaboration, accelerating innovation, and contributing to a healthier, more sustainable future.
